Manjari Lahiri (@SgRheumer) header
Manjari Lahiri (@SgRheumer) profile picture

Rheumatologist, A/Prof @NUSMedicine 🇸🇬 @NUHSofficial || @AIIMS_NewDelhi ‘90-‘99 🇮🇳 || #RheumTwitter🦴|| #MedEd || Mummy of 2 || Dreamer || Views my own

Singapore
Joined December 2010
Photo by Manjari Lahiri (@SgRheumer)Photo by Manjari Lahiri (@SgRheumer)Photo by Manjari Lahiri (@SgRheumer)Photo by Manjari Lahiri (@SgRheumer)Photo by Manjari Lahiri (@SgRheumer)Photo by Manjari Lahiri (@SgRheumer)Photo by Manjari Lahiri (@SgRheumer)Photo by Manjari Lahiri (@SgRheumer)Photo by Manjari Lahiri (@SgRheumer)Photo by Manjari Lahiri (@SgRheumer)
And it’s a wrap for #APLAR2025 Well done team @NUHSofficial 👏🏽👏🏽
7
312
Day1 #APLAR2025 Focus on #lupus 🦋 The new TRM-SLE tinyurl.com/TRMSLE elegantly elucidated by @EricFMorand focusing on indices that alter how patients #feel, #function or #survive And @Lupusreference very energetic talk summarising current lupus trials Exciting times 🤩
2
174
Manjari Lahiri retweeted
Congratulations to Dr. Bhatla from the AIIMS 1990 batch. We are proud to have been her students! @Amitvermamds @SgRheumer @SleepnLetSleep @vibhusharmamd
2
1
4
689
4-year data from TREAT EARLIER @TheLancetRheum ⬇️ risk of seronegative RA for MTX arm (& 💉 IM triamcinolone) How about just the IM 💉 steroid ? Somehow not really convinced that treating with MTX makes sense? What do you think? 🤔 #RheumTwitter thelancet.com/journals/lanrh…
1
148
Shucks 😭 didn't make it! Oh well, keep trying💪 😂 #ACR24
Congrats to the influencers of #ACR24 & thanks for all your posts sharing knowledge from the conference!!! 🥳 @ACRheum @rheum_cat @RheumNow @MithuRheum @EBRheum @noellealicia242 @NamrataRheum @realcc @rheumarhyme #Rheumatology
1
273
So many options 🤩 But let's not forget that early diagnosis, close monitoring, improved adherence to treatment and minimising GC toxicity will probably have a larger impact in terms of absolute patient numbers and reach #LupusNephritis #Lupus
✅ Current pipeline of investigational agents / drug development in #Lupus, updated with #ACR2024 data ⬇️ What would you add? Which ones are the most promising? There is truly hope for patients with #SLE. Please do let me know if I have forgotten something & I will reupdate.
2
296
Not investing any time soon 😅 but this is a great summary!
B-cell Depletion Race in AID 1 Identifying key players in this race could present an outstanding investment opportunity. Here’s how I approach this emerging field: $SANA $IPSC $FATE $CRBU $CRSP $ALLO $PSTX $ACET $TAK $NKTX $LEGN $NVS $BMY $AZN $AMGN $RHHBY $MRK $CGEM $IGMS $XNCR
1
164
Manjari Lahiri retweeted
All-caps abstract text throw-down by Michelle Petri re:fractures in SLE 😆 I keep saying this; our obsesssion with vitamin d is not commensurate w/reality It's. The. Prednisone. #ACR24 @RheumNow Abstr#2679 #ACRBest
1
7
27
2,789
💡 New hope for severe/refractory #SLE: A-319 (CD3 x CD19 TCE) shows rapid and safe immune reset! ✅ Rapid B-cell depletion, autoantibody reduction, & organ improvement by W2 ✅ No CRS or ICANS observed 📊 Could this be a game-changer in SLE therapy? @Dr_AndreRibeiro #ACR24 – at Washington, DC
1
23
44
3,100
#ACR24: The year of cell therapy in autoimmune diseases and redefining Tx paradigms! 🧬 Breakfree-1 CD19 CAR-T therapy shows sustained clinical remission in refractory #SLE and a safer profile. 🔬 Next-gen technology on the way. Stay tuned for more! @Dr_AndreRibeiro – at Washington, DC
11
2
14
2,111
Manjari Lahiri retweeted
Sarcoidosis is a granulomatous disorder that affects people of all racial and ethnic backgrounds. The pathogenesis of sarcoidosis remains incompletely understood. Learn more in the latest Interactive Medical Case: nej.md/3UQ4s6V
3
60
3
270
29,597
Clinical year in PREVIEW Grace Wright @AWIRGROUP #ACR24 1/3 💥Biomarkers in SLE Non-invasive urinary panel predicts BOTH active proliferative LN AND response ✅ 💥GC sparing in SLE Disruption of E3-X novel E3-ligase ⬆️GILZ
1
1
4
506
Clinical year in PREVIEW Grace Wright @AWIRGROUP #ACR24 2/3 💥Cell Rx in SLE 💡Autologous anti-CD19 B 💡NEX-T 💡CD3XCD19 TCE Safety ✅ low CRS, no ICANS, deep depletion 👎🏽infections, neutropenia
1
1
2
248
Clinical year in PREVIEW Grace Wright @AWIRGROUP #ACR24 3/3 💥Anti-obesity meds in RA/ AID Observational databases (FORWARD - pan-US, community practices) 💪🏽 Improved PRO, APR 👉🏽But ONLY in obese pts ❓⬇️CV risk New paradigm of combination Rx?
1
2
197
Late breaking L19 Alexei Grom #ACR24 Emapalumab: anti IFN y Ab, MAS in Still’s dz 💡Data pooled from 2 obs studies, n=49, mostly kids ✅ 1° outcome CR of ALL MAS criteria=53%, 69% if LDH excluded, 82% investigator determined remission, 95% survival 👎🏽TEAE = viral infections🦠
2
1
269
✨ Breaking at #ACR24 KN5501 CAR-NK therapy is emerging as a safer and effective alternative to CAR-T for relapsed and refractory SLE patients. ✅ 50% DORIS remission ✅ 68.8% LLDAS (>6 months follow-up) ✅ No Grade ≥2 CRS or ICANS @Dr_AndreRibeiro – at Washington, DC
1
8
1
28
2,743
🔍 Why CAR-NK therapy works? 💥 Deep B-cell depletion + naïve B-cell reset. 💥 Complement normalization (C3, C4). 💥 Anti-dsDNA antibody reduction. ⚠️ Safety First! ⚠️ 💡 No severe CRS 💡 No ICANS 💡 No major infections @Dr_AndreRibeiro – at Washington, DC
1
3
4
622
⁉️ CAR-NK therapy will redefine treatments for lupus ⁉️ ✅️ Targeted, very safe immune modulation with off-the-shelf availability. ☢️ As a CAR-T alternative, KN5501 represents a major breakthrough with further studies required to verify this data. @Dr_AndreRibeiro #ACR24 – at Washington, DC
5
1
5
1,272
Late breaking L15 Phil Conaghan #ACR24 Phase 2 DBPCRCT novel neurotrophin NT3 ➖or + Ig = LEVI-4 Knee #OA n = 518, WOMAC >=20, KL >=2 N=518, 3 doses Achieved 1° outcome=change in WOMAC @ 17w stiffness, function, PGA ✅ Without concerning SAE, esp rapidly progressive OA
1
1
233
Late breaking L17 #ACR24 More excitement in the cellular Rx field! N=22 refractory lupus open label (China) ✨CAR-NK (not T) ✨Allogenic! Avg F/up 7m, max 14m ⬇️ SLEDAI2K, PGA SRI4 ✅ DORIS remission 6m=50-%, 12m=💯 ✨With NO CRS >=2/ ICANS/ infections! Needs replication!
2
2
310